Last reviewed · How we verify
intravitreal injection of RC28-E
At a glance
| Generic name | intravitreal injection of RC28-E |
|---|---|
| Sponsor | RemeGen Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of RC28-E Injection in Diabetic Macular Edema (PHASE2)
- Evaluation of RC28-E Injection in Diabetic Retinopathy (PHASE2)
- Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema (PHASE3)
- Efficacy and Safety of RC28-E Versus Aflibercept (PHASE3)
- Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration (PHASE1, PHASE2)
- Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravitreal injection of RC28-E CI brief — competitive landscape report
- intravitreal injection of RC28-E updates RSS · CI watch RSS
- RemeGen Co., Ltd. portfolio CI